Once-yearly zoledronic acid in the prevention of osteoporotic bone fractures in postmenopausal women

Clinical Interventions in Aging

Volumn 3, Issue 3, 2008, Pages 445-451

  Lambrinoudaki, Irene ^a,b   Vlachou, Sophia ^a   Galapi, Fotini ^a   Papadimitriou, Dimitra ^a   Papadias, K ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b NONE   (Greece)

Author keywords

Bisphosphonate; Postmenopausal osteoporosis; Zoledronic acid

Indexed keywords

ALENDRONIC ACID; AMINO TERMINAL TELOPEPTIDE; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; CREATININE; CYTOCHROME P450; GERANYLTRANSFERASE; PLACEBO; VITAMIN D; ZOLEDRONIC ACID;

ARTHRALGIA; BONE BIOPSY; BONE DENSITY; BONE METABOLISM; BONE METASTASIS; BONE MINERALIZATION; BONE NECROSIS; BONE PAIN; CALCIUM BLOOD LEVEL; CELL DIFFERENTIATION; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG EXCRETION; DRUG EXPOSURE; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; ENZYME INHIBITION; FLU LIKE SYNDROME; FRAGILITY FRACTURE; HEART ATRIUM FIBRILLATION; HUMAN; HYPERCALCEMIA; HYPOCALCEMIA; JAW DISEASE; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; MORTALITY; MYALGIA; OSTEOBLAST; OSTEOLYSIS; PATHOLOGIC FRACTURE; POSTMENOPAUSE OSTEOPOROSIS; RECOMMENDED DRUG DOSE; REVIEW; RISK REDUCTION; SINGLE DRUG DOSE; TREATMENT INDICATION;

BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; DRUG ADMINISTRATION SCHEDULE; FEMALE; FRACTURES, BONE; HUMANS; IMIDAZOLES; INFUSIONS, INTRAVENOUS; OSTEOPOROSIS, POSTMENOPAUSAL; POSTMENOPAUSE; TREATMENT OUTCOME;

EID: 54949134820     PISSN: 11769092     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. Bamias A, Kastritis E, Bamia C, et al. 2005. Osteonecrosis of the jaw in cancer afer treatment with bisphosphonates: incidence and risk factors. J Clin Oncol, 23:8580-7.
2. Benford HL, McGowan NW, Helfrich MH, et al. 2001. Visualization of biphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro. Bone, 28:465-73.
3. Black DM, Delmas PD, Eastell R, et al; HORIZON Pivotal Fracture Trial. 2007. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med, 356:1809-22.
4. Body J. 2006. Breast cancer: Bisphosphonates therapy for metastatic bone disease. Clin Cancer Res, 12:6258-63.
5. Boissier S, Ferreras M, Peyruchaud O, et al. 2000. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res, 60:2949-54.
6. Brufsky A. 2006. Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST update. Semin Oncol, 33:13-17.
7. Chen T, Berenson J, Vescio R, et al. 2002. Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J Clin Pharmacol, 42:1228-36.
8. Consensus Development Conference. 1993. Diagnosis, prophylaxis and treatment of osteoporosis. Am J Med, 94:646-50.
9. Coxon FP, Helfrich MH, Van't Hof R, et al. 2000. Protein geranylgeranylation is required for osteoclast formation, function, and survival: Inhibition by biphosphonates and GGTI-298. J Bone Miner Res, 15:1467-76.
10. Devogelaer JP, Brown JP, Burckhardt P, et al. 2007. Zoledronic acid efficacy and safety over five years in postmenopausal osteoporosis. Osteoporos Int, 18:1211-18.
11. Geusens PP, Lems WF. 2007. Fracture prevention in postmenopausal women with osteoporosis by an annual infusion of zoledronic acid. Ned Tijdschr Geneeskd, 151:1445-8.
12. Gnant MF, Mlineritsch B, Luschin-Ebengreuth G, et al; Austrian Breast and Colorectal Cancer Study Group. 2007. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol, 25:820-8.
13. Green JR. 2001. Chemical and biological prerequisities for novel biphosphonate molecules: Results of comparative preclinical studies. Semin Oncol, 28(Suppl 6):4-10.
14. Green JR. 2002. Preclinical pharmacology of zoledronic acid. Semin Oncol, 29:3-11.
15. Hadji P. 2007. Reducing the risk of bone loss associated with breast cancer treatment. Breast, 16S3:10-15.
16. Hosking D, Lyles K, Brown JP, et al. 2007. Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate. J Bone Miner Res, 22:142-8.
17. Kanis JA, Delmas P, Burckhardt P, et al. for the European Foundation for Osteoporosis and Bone Disease. 1997. Guidelines for diagnosis and treatment of osteoporosis. Osteoporos Int, 7:390-406.
18. Kenji Kawada, Hironobu Minami, Keniichi Okabe, et al. 2005. A Multicenter and Open Label Clinical Trial of Zoledronic Acid 4 mg in Patients with Hypercalcemia of Malignancy. Jpn J Clin Oncol, 35:28-33.
19. Krueger CD, West PM, Sargent M, et al. 2007. Bisphosphonate-induced osteonecrosis of the jaw. Ann Pharmacother, 41(2):276-84.
20. Kut V, Mehta J, Tariman J, et al. 2004. Osteonecrosis of the jaw in Myeloma Patients Receiving Pamidronate or Zoledronate. Blood, 104:4933.
21. Lambrinoudaki I, Christodoulakos G, Botsis D. 2006. Biphosphonates. Ann N Y Acad Sci, 1092:397-402.
22. Li EC, Davis LE. 2003. Zoledronic acid: a new parentera] biphosphonate. Clin Ther, 25:2669-708.
23. Looker AC, Johnston CC Jr, Wahner HW, et al. 1995. Prevalence of low mineral bone density in older U.S. women from NHANES III. J Bone Miner Res, 10:796-802.
24. Lyles KW, Colón-Emeric CS, Magaziner JS, et al; HORIZON Recurrent Fracture Trial. 2007. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med, 357:1799-809.
25. McClung M, Recker R, Miller P, et al. 2007. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate. Bone, 41:122-8.
26. Murad OM, Arora S, Farag AF, et al. 2007. Bisphosphonates and osteonecrosis of the jaw: a retrospective study. Endocr Pract, 13:232-8.
27. Nancollas GH, Tang R, Phipps RJ, et al. 2006. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone, 38:617-27.
28. Perry CM, Figgitt DP. 2004. Zoledronic acid: a review of its use in patients with advanced cancer. Drugs, 64:1197-211.
29. Recker RR, Delmas PD, Halse J, et al. 2008. The effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure. J Bone Miner Res, 23:6-16.
30. Reid IR, Brown JP, Burckhardt P, et al. 2002. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med, 346:653-61.
31. Reid IR, Miller P, Lyles K, et al. 2005. Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. N Engl J Med, 353:898-908.
32. Reinholz GG, Getz B, Pederson L, et al. 2000. Biphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts. Cancer Res, 60:6001-7.
33. Rosen LS, Gordon D, Antonio BS, et al. 2001. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J, 7:377-87.
34. Ryan CW, Huo D, Bylow K, et al. 2007. Suppression of bone density loss and bone turnover in patients with hormone-sensitive prostate cancer and receiving zoledronic acid. BJU Int, 100:70-5.
35. Saad F. 2002. Zoledronic acid significantly reduces pathologic fractures in patients with advanced-stage prostate cancer metastatic to bone. Clin Prostate Cancer, 1:145-52.
36. Saag K, Lindsay R, Kriegman A, et al. 2007. A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density. Bone, 40:1238-43.
37. Siris ES, Miller PD, Barrett-Connor E, et al. 2001. Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: Results from the National Osteoporosis Risk Assessment. JAMA, 286:2815-22.
38. Smith MR, Eastham J, Gleason D, et al. 2003. Randomized controlled trial of zoledronic acid to prevent bone loss in men undergoing androgen deprivation therapy for nonmetastatic prostate cancer. J Urol, 169:2008-12.
39. Smith MR. 2006. Treatment-related osteoporosis in men with prostate cancer. Clin Cancer Res, 12:6315-19.
40. World Health Organization. Prevention and management of osteoporosis. WHO Technical Report Series 921 [online]. URL: http://whiqlibdoc.who.int/ trs/WHO_TRS_921.pdf.
41. Widler L, Jaeggi KA, Glatt M, et al. 2002. Highly potent geminal biphosphonates. From pamidronate disodium (Aredia) to zoledronic acid (Zometa). J Med Chem, 45:3721-38.
42. Wutzl A, Eisenmenger G, Hoffmann M, et al. 2006. Osteonecrosis of the jaws and bisphosphonate treatment in cancer patients. Wien Klin Wochenschr, 118:473-8.
43. Yeh HS, Berenson JR. 2006. Treatment for myeloma bone disease. Clin Cancer Res, 12:6279-84.